MyFinsight
Home
Blog
About
Contact
Download
Download image
Net proceeds from
issuance of preferred...
$15,019,700
Net proceeds from
issuance of common stock
$2,634,190
Borrowings on short-term
notes payable
$2,455,911
Net cash provided by
financing activities
$16,781,273
Canceled cashflow
$3,328,528
Net increase
(decrease) in cash and cash...
$7,534,886
Canceled cashflow
$9,246,387
Payments on short-term
notes payable
$3,328,528
Amortization of debt discount
and closing costs
$771,437
Stock-based compensation
expense
$642,364
Accounts payable and
accrued expenses
$203,144
Common stock for
services rendered
$126,140
Net cash used in
operating activities
-$9,246,387
Canceled cashflow
$1,743,085
Net loss
-$9,842,487
Prepaid expenses and
other current assets
$1,007,286
Stock-based compensation
recapture expense
-$86,617
Other receivables
$53,082
Back
Back
Cash Flow
source: myfinsight.com
ORAGENICS INC (OGEN)
ORAGENICS INC (OGEN)